ArticleActa pharmacologica Sinica2026

Discovery of a potent and orally bioavailable type Ⅰ PRMTs inhibitor for triple-negative breast cancer treatment.

Shu-Yan Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.